Latest Editas Medicine News & Updates

See the latest news and media coverage for Editas Medicine. We track all announcements, press releases, and industry mentions in real time, all in one place.

Editas Medicine

Gene editing company developing CRISPR medicines

editasmedicine.com

Headquarters: Cambridge, United States
Founded year: 2013
Company type: Public company
Number of employees: 200–500

Last updated Today

Latest news about Editas Medicine

In short: Editas Medicine shifted its strategic focus toward in vivo gene editing, bolstered by a $319.4 million public offering and positive preclinical data.

Company announcements

June 11 Editas Medicine

Editas Medicine reports EDIT-401 reduces LDL-C in NHPs

A single dose achieved over 90% mean reduction in LDL-C, ApoB, and Lp(a) in non-human primates.

May 29 Editas Medicine

Editas Medicine completed a $319.4M public offering

The company will use proceeds to advance its lead candidate EDIT-401 and build long-term value.

May 26 Editas Medicine

Editas Medicine announces proposed public offering of common stock

The offering includes common stock and warrants, with Cantor and Wells Fargo as joint book-running managers.

May 21 Editas Medicine

Editas Medicine presents preclinical data for EDIT-401 reducing LDL-C

A single dose achieved >90% LDL-C reduction in non-human primates by upregulating LDLR.

Media coverage

June 13 The Globe and Mail

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious...

May 26 Yahoo Finance

Editas Medicine Announces Proposed Public Offering

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...

May 6 Yahoo Finance

EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Editas narrows Q1 loss as costs fall, but revenues drop sharply. Pipeline focus shifts to in vivo gene editing and lead candidate EDIT-401.

March 14 Yahoo Finance

Editas Medicine Details In Vivo CRISPR Plan, Targets Year-End Human Proof-of-Concept for EDIT-401

Editas Medicine (NASDAQ:EDIT) executives outlined the company’s in vivo CRISPR gene-editing strategy...

Never miss news about Editas Medicine

Track Editas Medicine and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Editas Medicine competitors & trending companies

Browse news for competitors to Editas Medicine and other trending companies.